This study defines SCRN2 as a novel tumor suppressor in TNBC to suppress cancer progression and enhance PARP inhibitor sensitivity through stabilizing KMT2C and reveals SCRN2 as a potential biomarker and therapeutic target for TNBC. This evidence concerns the gene SCRN2 and cancer.